Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN027
MIFTS: 57

Adenomyosis

Categories: Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenomyosis

About this section

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 57 12 74 20 44 15 17
Endometriosis of Uterus 12 15 71 32
Endometriosis of Myometrium 12
Endometriosis, Myometrium 12
Endometriosis Interna 12
Uterine Adenomyosis 12

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal vs. x-linked dominant


HPO:

31
adenomyosis:
Inheritance autosomal dominant inheritance x-linked dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:288
OMIM® 57 600458
ICD9CM 34 617.0
MeSH 44 D062788
NCIt 50 C6996
SNOMED-CT 67 76376003
ICD10 32 N80.0
MedGen 41 C0341858
UMLS 71 C0341858
Sources

Summaries for Adenomyosis

About this section
GARD : 20 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to adenomyoma and leiomyoma, uterine. An important gene associated with Adenomyosis is PGR (Progesterone Receptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dienogest and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include uterus, endothelial and pituitary, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : 12 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM® : 57 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458) (Updated 05-Mar-2021)

Wikipedia : 74 Adenomyosis is a medical condition characterized by the growth of cells that build up the inside of the... more...

Sources

Related Diseases for Adenomyosis

About this section

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 506)
# Related Disease Score Top Affiliating Genes
1 adenomyoma 30.8 PGR MME GNRH1 CTNNB1
2 leiomyoma, uterine 30.8 PGR GNRH1 ESR1 CYP19A1
3 amenorrhea 30.7 PRL GNRH1 CYP19A1
4 ovarian cyst 30.6 VEGFA PRL GNRH1 CYP19A1
5 ectopic pregnancy 30.5 VEGFA PGR HOXA10 GNRH1
6 leiomyosarcoma 30.5 VEGFA TP53 PGR ESR1
7 infertility 30.5 PRL PGR HOXA10 GNRH1 ESR2 CYP19A1
8 leiomyoma 30.4 PGR OXTR MME GNRH1 ESR2 ESR1
9 leiomyomatosis 30.4 PGR GNRH1 ESR1
10 endometriosis 30.4 VEGFA PTGS2 PGR MMP2 HOXA10 GNRH1
11 adenocarcinoma 30.3 VEGFA TP53 PTGS2 MMP9 MMP2 CTNNB1
12 intravenous leiomyomatosis 30.3 PGR MME ESR1
13 endometriosis of ovary 30.3 PGR GNRH1 ESR2 ESR1 CYP19A1
14 sarcoma 30.2 VEGFA TP53 PTGS2 CXCL8 CTNNB1
15 adenosarcoma 30.2 TP53 PGR MME ESR1
16 endometritis 30.2 PGR OXT ESR1 CXCL8
17 placenta disease 30.1 VEGFA OXT CXCL8
18 progesterone resistance 30.1 PGR ESR2 ESR1
19 preterm premature rupture of the membranes 30.0 TIMP2 OXT MMP9 MMP2 CXCL8
20 placenta accreta 30.0 VEGFA OXT CDH1
21 in situ carcinoma 30.0 TP53 PGR ESR1 CYP19A1 CTNNB1 CDH1
22 uterine corpus adenosarcoma 30.0 PGR MME ESR1
23 endometrial adenocarcinoma 30.0 VEGFA TP53 PGR ESR2 ESR1 CTNNB1
24 pain agnosia 29.9 PTGS2 OXT NGF
25 ovarian hyperstimulation syndrome 29.9 VEGFA GNRH1 CYP19A1
26 endometrial hyperplasia 29.9 VEGFA TP53 PGR HOXA10 ESR2 ESR1
27 female reproductive endometrioid cancer 29.8 TP53 PGR ESR1 CTNNB1
28 smooth muscle tumor 29.8 PGR MMP2 MME ESR1
29 interstitial cystitis 29.8 NGF CXCL8 CDH1
30 papillary adenocarcinoma 29.8 TP53 PGR CDH1
31 ureteral obstruction 29.8 TP53 PTGS2 CTNNB1
32 vaginal discharge 29.7 PGR OXT GNRH1 ESR1 CYP19A1 CXCL8
33 myoma 29.6 TP53 PGR OXT MME HOXA10 GNRH1
34 hydronephrosis 29.5 VEGFA MMP9 MME CYP19A1 CXCL8
35 cystitis 29.5 VEGFA TP53 PTGS2 NGF CXCL8 CDH1
36 tubular adenocarcinoma 29.5 PGR MME ESR1 CTNNB1 CDH1
37 wilms tumor 1 29.4 TP53 PGR MME ESR1 CTNNB1
38 pelvic organ prolapse 29.3 TP53 PGR MMP9 MMP2 ESR2 ESR1
39 carcinosarcoma 29.3 TP53 PGR MME CTNNB1 CDH1
40 breast fibroadenoma 29.3 TP53 TIMP2 PGR MME ESR1 CYP19A1
41 estrogen excess 29.2 PRL PGR GNRH1 ESR2 ESR1 CYP19A1
42 uterine carcinosarcoma 29.1 TP53 PTGS2 PGR MME ESR2 CTNNB1
43 endometrial stromal sarcoma 29.1 TP53 PGR OXTR MMP9 MMP2 MME
44 endometrial disease 29.0 PTGS2 PGR OXT HOXA10 GNRH1 ESR1
45 endometrial cancer 28.8 VEGFA TP53 TIMP2 PGR MMP9 MMP2
46 uterine anomalies 11.0
47 myofibroma 10.5
48 extracranial arteriovenous malformation 10.5 MMP9 MMP2
49 glassy cell carcinoma of the cervix 10.5 PGR ESR1
50 breast intraductal papillomatosis 10.5 PGR ESR1

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis
Sources

Symptoms & Phenotypes for Adenomyosis

About this section

Human phenotypes related to Adenomyosis:

31
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 31 HP:0001892
2 dysmenorrhea 31 HP:0100607
3 abnormality of the genitourinary system 31 HP:0000119

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM®:

600458 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Adenomyosis:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 HOXA10
2 homeostasis/metabolism MP:0005376 10.49 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
3 behavior/neurological MP:0005386 10.47 CTNNB1 CYP19A1 ESR1 ESR2 MME MMP9
4 growth/size/body region MP:0005378 10.46 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
5 endocrine/exocrine gland MP:0005379 10.41 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
6 integument MP:0010771 10.41 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
7 immune system MP:0005387 10.4 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
8 digestive/alimentary MP:0005381 10.35 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
9 hematopoietic system MP:0005397 10.33 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 MMP2
10 nervous system MP:0003631 10.33 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 HOXA10
11 muscle MP:0005369 10.23 CTNNB1 CYP19A1 ESR1 ESR2 MMP2 MMP9
12 neoplasm MP:0002006 10.21 CDH1 CTNNB1 ESR1 ESR2 GNRH1 MMP2
13 liver/biliary system MP:0005370 10.18 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 MME
14 normal MP:0002873 10.17 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
15 limbs/digits/tail MP:0005371 10.1 CTNNB1 ESR1 ESR2 HOXA10 MMP9 PGR
16 no phenotypic analysis MP:0003012 10.07 CDH1 CTNNB1 ESR1 ESR2 NGF OXTR
17 reproductive system MP:0005389 10.03 CDH1 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1
18 renal/urinary system MP:0005367 9.96 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 MMP9
19 respiratory system MP:0005388 9.56 CTNNB1 ESR1 ESR2 MMP2 MMP9 PTGS2
20 skeleton MP:0005390 9.4 CTNNB1 CYP19A1 ESR1 ESR2 GNRH1 HOXA10
Sources

Drugs & Therapeutics for Adenomyosis

About this section

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dienogest Approved Phase 4 65928-58-7
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Ibuprofen Approved Phase 4 15687-27-1 3672
5
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
6
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
7
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
8
Polyestradiol phosphate Approved Phase 4 28014-46-2
9
Buserelin Approved, Investigational Phase 4 57982-77-1
10 Contraceptives, Oral Phase 4
11 Contraceptive Agents, Male Phase 4
12 Contraceptives, Oral, Combined Phase 4
13 Hormones Phase 4
14 Estrogens Phase 4
15 Antineoplastic Agents, Hormonal Phase 4
16 Progestins Phase 4
17 Estradiol 3-benzoate Phase 4
18 Triptorelin Pamoate Phase 4
19 Estradiol 17 beta-cypionate Phase 4
20
Lactitol Approved, Investigational Phase 2, Phase 3 585-86-4 157355
21
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
22
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
23
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
24
Ethanol Approved Phase 2, Phase 3 64-17-5 702
25
Ramosetron Investigational Phase 3 132036-88-5
26 Trace Elements Phase 3
27 Micronutrients Phase 3
28 Aromatase Inhibitors Phase 2, Phase 3
29 Estrogen Receptor Antagonists Phase 2, Phase 3
30 Estrogen Antagonists Phase 2, Phase 3
31 Contraceptives, Postcoital Phase 2, Phase 3
32 Analgesics Phase 3
33 Prolactin Release-Inhibiting Factors Phase 3
34
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
35
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
36
Quinagolide Approved, Investigational Phase 2 87056-78-8, 97805-50-0 105105
37 Neurotransmitter Agents Phase 2
38 Dopamine Agents Phase 2
39 Dopamine agonists Phase 2
40
Bromocriptine Approved, Investigational Phase 1 25614-03-3 31101
41 Antiparkinson Agents Phase 1
42
Drospirenone Approved Early Phase 1 67392-87-4 68873
43
Racepinephrine Approved 329-65-7 838
44
Epinephrine Approved, Vet_approved 51-43-4 5816
45
Leuprolide Approved, Investigational 53714-56-0 3911 657181
46
Povidone-iodine Approved 25655-41-8
47
Povidone Approved 9003-39-8 131751496
48
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
49
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
50
Iodine Approved, Investigational Early Phase 1 7553-56-2 807

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Unknown status NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
2 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
3 Use of Oxytocin in MRI-HIFU Treatment Enrolling by invitation NCT03937401 Phase 4 Oxytocin
4 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
5 Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study Not yet recruiting NCT04356664 Phase 4 GnRH agonist
6 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
7 Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study Unknown status NCT02437175 Phase 3
8 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
9 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
10 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
11 Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
12 Mifepristone Versus Placebo to Treat Adenomyosis: a Double-blind, Multicentre，Randomized Clinical Trial Completed NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
13 Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
14 Phase III Trial to Assess Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI Outcomes in Infertile Women Presenting With Adenomyosis. Not yet recruiting NCT03940807 Phase 3 11.25mg GnRH agonist;0.1 mg GnRH agonist;25 µg transdermal oestradiol
15 Single Blinded Randomized Controlled Study of Symptom Improvement After Uterine Artery Embolization (UAE) Versus Ultrasound Guided Percutaneous/Transvaginal Microwave Ablation, Evaluated by Validated Questionnaires Not yet recruiting NCT04209127 Phase 2, Phase 3
16 Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis Unknown status NCT02587000 Phase 2 Ulipristal acetate;Placebo
17 Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial Completed NCT01601366 Phase 2 Combined oral contraceptives
18 A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis Recruiting NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
19 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
20 Vaginal Bromocriptine for the Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
21 A Study of Cooperative Network of Diagnosis and Treatment of Uterine Adenomyosis. Unknown status NCT03230994
22 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
23 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
24 Health-Related Quality of Life Among Women Receiving Hysterectomy in National Taiwan University Hospital Unknown status NCT00155870
25 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
26 A Multi-omics Study on the Tumorigenesis of Adenomyosis Unknown status NCT03742843
27 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis : A Preliminary Study Unknown status NCT01259180
28 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
29 The Effect in Term of Ovarian Reserve Modification of Adding Prophylactic Bilateral Salpingectomy (PBS) to TLH for Preventing Ovarian Cancer Unknown status NCT02086344
30 A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Paracervical Block Before Total Laparoscopic Hysterectomy for Postoperative Pain Control (PALAPA): Unknown status NCT03792009 5% bupivacaine;Normal saline
31 Prospective Cohort Study to Compare to 2-channel and Multiple Channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
32 Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Can Be Useful Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
33 Cohort Study of Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648
34 The Diagnostic Accuracy of Hysteroscopic Endomyometrial Biopsy in Adenomyosis Completed NCT02340533
35 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
36 AMH Levels Change During Treatment With GnRh Agonist: A Prospective Observational Study. Completed NCT02086279 GnRH analogue
37 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
38 Sonohysterography and 3D Ultrasonography Versus Diagnostic Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501
39 Can the Effect of Levonorgestrel Intrauterine System for Treatment of Adenomyosis be Predicted at Baseline Visit? Completed NCT03104309
40 Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri Completed NCT03890042 Dienogest group;Gestodene-Ethinyl Estradiol
41 Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part I Completed NCT02201719
42 A Multicenter Observational Study of Diphereline 3.75 mg Treatment Effectiveness in Russian Women Suffering From Internal Genital Endometriosis Completed NCT03586063
43 The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization Completed NCT02056717 Dexamethasone;Normal saline
44 Short and Long Term Outcomes of Uterine Artery Embolization. Completed NCT00354471
45 Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery Completed NCT01463462
46 Randomized Trial of Laparoscopic Versus Abdominal Hysterectomy for Benign Indications and Impact on Surgical Success Completed NCT01793584
47 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? A Randomized Controlled Trial Comparing 3D Laparoscopy Versus Standard Laparoscopy Completed NCT02192606
48 Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial Completed NCT01628432
49 Value of Transvaginal Ultrasound, Transvaginal Sonographic Elastography and MRI for the Diagnosis of Adenomyosis Recruiting NCT04665414
50 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms and Gastrointestinal Symptoms Recruiting NCT02495311

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Sources

Genetic Tests for Adenomyosis

About this section
Sources

Anatomical Context for Adenomyosis

About this section

MalaCards organs/tissues related to Adenomyosis:

40
Uterus, Endothelial, Pituitary, Smooth Muscle, Breast, Cervix, Bone
Sources

Publications for Adenomyosis

About this section

Articles related to Adenomyosis:

(show top 50) (show all 2818)
# Title Authors PMID Year
1
Adenomyosis: evidence for genetic cause. 57 61
7762596 1995
2
The elusive adenomyosis of the uterus. Its historical past and its present state of recognition. 57 61
13890115 1962
3
Dysmenorrhea in patients with adenomyosis: A clinical and demographic study. 61
32325268 2021
4
TGF-β1 Neutralization Improves Pregnancy Outcomes by Restoring Endometrial Receptivity in Mice with Adenomyosis. 61
32909191 2021
5
The cannabinoid receptor CB1 affects the proliferation and apoptosis of adenomyotic human uterine smooth muscle cells of the junctional zone: a mechanism study. 61
33531043 2021
6
Treatment of juvenile cystic adenomyoma by sclerotherapy with alcohol instillation: a case report. 61
33545412 2021
7
Peritoneal Retraction Pocket Defects and Their Important Relationship with Pelvic Pain and Endometriosis. 61
32474173 2021
8
Risk factors of vaginal cuff infection in women undergoing laparoscopic hysterectomy for benign gynecological diseases. 61
33590565 2021
9
Serum anti-Mullerian hormone, prolactin and estradiol concentrations in infertile women with endometriosis. 61
33274686 2021
10
Is primary dysmenorrhea a precursor of future endometriosis development? 61
33569996 2021
11
Decreased Indian hedgehog signaling activates autophagy in endometriosis and adenomyosis. 61
33434164 2021
12
Diagnosis and treatment of adenomyosis. 61
33593948 2021
13
Adenomyosis and infertility: the role of the junctional zone. 61
33587014 2021
14
Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis. 61
33590656 2021
15
Possible involvement of neuropeptide and neurotransmitter receptors in Adenomyosis. 61
33602248 2021
16
Endometrial stromal cell proteomic analysis reveals LIM and SH3 protein 1 (LASP1) plays important roles in the progression of adenomyosis. 61
33543750 2021
17
The prognostic role of ovarian endometriosis in symptomatic adenomyosis patients underwent uterine artery embolization. 61
33548995 2021
18
Talin1 Induces Epithelial-Mesenchymal Transition to Facilitate Endometrial Cell Migration and Invasion in Adenomyosis Under the Regulation of microRNA-145-5p. 61
33537874 2021
19
Impaired decidualization of human endometrial stromal cells from women with adenomyosis. 61
33533396 2021
20
Laparoscopic adenomyomectomy combined with levonorgestrel-releasing intrauterine system in the treatment of adenomyosis: Feasibility and effectiveness. 61
33174318 2021
21
Concomitant Adenomyosis among Patients with Asherman Syndrome. 61
32712321 2021
22
Endometrial causes of recurrent pregnancy losses: endometriosis, adenomyosis, and chronic endometritis. 61
33581856 2021
23
Effects of Etonogestrel implants on pelvic pain and menstrual flow in women suffering from adenomyosis or endometriosis: Results from a prospective, observational study. 61
33578561 2021
24
Association between uterine volume and pregnancy outcomes in adenomyosis patients undergoing frozen-thawed embryo transfer. 61
33243661 2021
25
Long-term durability of uterine artery embolisation for treatment of symptomatic adenomyosis. 61
33583017 2021
26
Uterine angiomyolipoma: a clinical analysis of 8 cases and literature review. 61
33569612 2021
27
Endometrial thickness in the evaluation of clinical response to medical treatment for deep infiltrating endometriosis: a retrospective study. 61
32926208 2021
28
Pregnancy and delivery outcomes in the women who have received adenomyomectomy: Performed by a single surgeon by a uniform surgical technique. 61
33495018 2021
29
Use of selective PGE2 receptor antagonists on human endometriotic stromal cells and peritoneal macrophages. 61
33543288 2021
30
Markers of human endometrial hypoxia can be detected in vivo and ex vivo during physiological menstruation. 61
33496337 2021
31
Specificity of the lactate dehydrogenase isoenzyme index as a preoperative screen for uterine sarcoma before myomectomy. 61
33070962 2021
32
MR imaging findings of unusual leiomyoma and malignant uterine myometrial tumors: what the radiologist should know. 61
33517507 2021
33
Magnetic Resonance Imaging in the Evaluation of Female Infertility. 61
33487486 2021
34
The "Speckle Sign" in the Diagnosis of Posterior Compartment Endometriosis. 61
33417291 2021
35
Risk factors for non-response and discontinuation of Dienogest in endometriosis patients: A cohort study. 61
32767677 2021
36
Utilization of radiomics to predict long-term outcome of magnetic resonance-guided focused ultrasound ablation therapy in adenomyosis. 61
32725335 2021
37
High-intensity focused ultrasound in the management of adenomyosis: long-term results from a single center. 61
33602049 2021
38
Impact of Adenomyosis on Women's Psychological Health and Work Productivity: A Comparative Cross-Sectional Study. 61
33464159 2021
39
Clinical outcomes after single-versus double-embryo transfers in women with adenomyosis: a retrospective study. 61
33386415 2021
40
ITRAQ-based proteomics analysis of tanshinone IIA on human ectopic endometrial stromal cells of adenomyosis. 61
33471216 2021
41
Ulipristal acetate use in adenomyosis: A randomized controlled trial. 61
33186772 2021
42
Adenomyosis of the inner and outer myometrium are associated with different clinical profiles. 61
33491057 2021
43
Prevalence of adenomyosis in endometrial cancer patients: a systematic review and meta-analysis. 61
33098006 2021
44
Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial. 61
33454995 2021
45
Adenomyosis and Infertility-Review of Medical and Surgical Approaches. 61
33573117 2021
46
Hypoxia and its possible relationship with endometrial receptivity in adenomyosis: a preliminary study. 61
33419445 2021
47
Systemic thromboembolism including multiple cerebral infarctions with middle cerebral artery occlusion caused by the progression of adenomyosis with benign gynecological tumor: a case report. 61
33430804 2021
48
Proteomic Analysis of Uterine Tissues During Peri-Implantation Period in Mice with Experimentally Induced Adenomyosis that Treated with anti-Ngf: Implications for Cell-Cell Adhesion and Metabolic Processes. 61
32676925 2021
49
Diffusion-weighted imaging of uterine adenomyosis: Correlation with clinical backgrounds and comparison with malignant uterine tumors. 61
33511748 2021
50
Spontaneous unscarred uterine rupture in a twin pregnancy complicated by adenomyosis: A case report. 61
33546004 2021
Sources

Variations for Adenomyosis

About this section
Sources

Expression for Adenomyosis

About this section
Search GEO for disease gene expression data for Adenomyosis.
Sources

Pathways for Adenomyosis

About this section

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.03 VEGFA TP53 TIMP2 PTGS2 PRL MMP9
2
ERK Signaling 63
Show member pathways
 13.77 VEGFA TP53 TIMP2 PTGS2 NGF GNRH1
3
GPCR Pathway 63
Show member pathways
 13.67 VEGFA TP53 TIMP2 PTGS2 NGF MMP9
4
TGF-Beta Pathway 63
Show member pathways
 13.52 VEGFA TP53 TIMP2 PRL NGF GNRH1
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.34 VEGFA TP53 PTGS2 PRL MMP9 MMP2
6
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.26 VEGFA TIMP2 NGF GNRH1 ESR2 ESR1
7
PI3K-Akt signaling pathway 36
Show member pathways
 12.98 VEGFA TP53 PTGS2 PRL NGF CTNNB1
8
Gastric cancer 36
Show member pathways
 12.77 TP53 PGR ESR2 ESR1 CTNNB1 CDH1
9
Development HGF signaling pathway 23
Show member pathways
 12.69 TP53 PTGS2 NGF ESR1 CTNNB1 CDH1
10
Glioma 36
Show member pathways
 12.66 TP53 MMP9 MMP2 ESR2 ESR1 CDH1
11
Relaxin signaling pathway 36
Show member pathways
 12.64 VEGFA PGR MMP9 MMP2 ESR2 ESR1
12
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.38 VEGFA PTGS2 ESR1 CTNNB1
13
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.38 TIMP2 NGF GNRH1 CTNNB1 CDH1
14
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.27 TP53 TIMP2 NGF GNRH1 CXCL8
15
Proteoglycans in cancer 36
12.27 VEGFA TP53 MMP9 MMP2 ESR1 CTNNB1
16
Transcriptional misregulation in cancer 36
12.26 TP53 MMP9 HOXA10 CXCL8
17
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.14 VEGFA NGF ESR2 CXCL8 CTNNB1
18
Pathways in cancer 36
12.05 VEGFA TP53 PTGS2 MMP9 MMP2 ESR2
19
Fluid shear stress and atherosclerosis 36
12.04 VEGFA TP53 MMP9 MMP2 CTNNB1
20
Adhesion 4
12.03 MMP9 MMP2 CTNNB1 CDH1
21
Integrated Breast Cancer Pathway 1
12.03 VEGFA TP53 ESR1 CYP19A1 CTNNB1 CDH1
22
Spinal Cord Injury 1
12.01 TP53 PTGS2 MMP9 CXCL8
23
Colorectal Cancer Metastasis 63
11.92 VEGFA TP53 PTGS2 MMP9 MMP2 CTNNB1
24
Angiogenesis (CST) 4
11.84 TIMP2 PTGS2 MMP9 MMP2
25
Interleukin-4 and 13 signaling 65
11.79 VEGFA TP53 PTGS2 MMP9 MMP2 CXCL8
26
Glucocorticoid receptor regulatory network 1
11.78 TP53 PRL CXCL8
27
Transcription_P53 signaling pathway 23
11.7 VEGFA TP53 MMP2 CTNNB1
28
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.7 MMP9 MMP2 CXCL8 CTNNB1 CDH1
29
LPA receptor mediated events 1
11.67 MMP9 MMP2 CXCL8
30
Lung fibrosis 1
11.65 MMP9 MMP2 CXCL8
31
Cell adhesion_ECM remodeling 23
11.63 TIMP2 MMP9 MMP2 CXCL8
32
Celecoxib Pathway, Pharmacodynamics 60
11.59 VEGFA PTGS2 MMP9 CTNNB1
33
Aryl Hydrocarbon Receptor 1
11.52 VEGFA PTGS2 ESR1
34
Hepatitis C and Hepatocellular Carcinoma 1
11.52 VEGFA TP53 PTGS2 CXCL8
35
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.52 VEGFA PTGS2 MMP9 MMP2 CXCL8
36
Photodynamic therapy-induced HIF-1 survival signaling 1
11.4 VEGFA TP53 PTGS2
37
Signaling mediated by p38-alpha and p38-beta 1
11.37 TP53 PTGS2 ESR1
38
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.35 MMP9 MMP2 CXCL8
39
Ovarian Infertility Genes 1
11.32 PGR ESR2 CYP19A1
40
A-beta Pathways: Uptake and Degradation 64
11.31 MMP9 MMP2 MME
41
Bladder cancer 36 1
11.3 VEGFA TP53 MMP9 MMP2 CXCL8 CDH1
42
Angiogenesis (WikiPathways) 1
11.17 VEGFA TIMP2 MMP9
43
Plasma membrane estrogen receptor signaling 1
11.17 MMP9 MMP2 ESR2 ESR1
44
A-beta Pathways: Plaque Formation and APP Metabolism 64
11.14 MMP9 MMP2 MME
45
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 60
10.21 ESR2 ESR1 CYP19A1
Sources

GO Terms for Adenomyosis

About this section

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 VEGFA TIMP2 PRL OXT NGF MMP9
2 adherens junction GO:0005912 9.46 VEGFA OXTR CTNNB1 CDH1
3 extracellular region GO:0005576 9.32 VEGFA TIMP2 PRL OXT NGF MMP9
4 flotillin complex GO:0016600 9.26 CTNNB1 CDH1

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 VEGFA PRL PGR OXTR OXT GNRH1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 VEGFA TP53 PGR HOXA10 ESR2 ESR1
3 positive regulation of gene expression GO:0010628 10.06 VEGFA TP53 NGF CXCL8 CTNNB1
4 positive regulation of apoptotic process GO:0043065 9.99 TP53 PTGS2 NGF MMP9 CTNNB1
5 negative regulation of apoptotic process GO:0043066 9.98 VEGFA TP53 PTGS2 NGF MMP9 GNRH1
6 heart development GO:0007507 9.96 TP53 OXTR OXT CTNNB1
7 aging GO:0007568 9.92 TIMP2 PTGS2 MME GNRH1
8 negative regulation of gene expression GO:0010629 9.88 VEGFA TP53 PGR ESR1 CXCL8 CTNNB1
9 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.83 VEGFA PTGS2 NGF
10 extracellular matrix disassembly GO:0022617 9.83 TIMP2 MMP9 MMP2
11 response to organic cyclic compound GO:0014070 9.83 PTGS2 OXTR OXT GNRH1
12 response to peptide hormone GO:0043434 9.81 OXTR OXT GNRH1
13 response to cytokine GO:0034097 9.8 TIMP2 PTGS2 OXTR
14 female pregnancy GO:0007565 9.78 PRL OXTR OXT GNRH1
15 memory GO:0007613 9.76 PTGS2 OXTR OXT NGF
16 lactation GO:0007595 9.73 VEGFA PRL OXTR
17 response to drug GO:0042493 9.73 TP53 TIMP2 PTGS2 OXTR CTNNB1 CDH1
18 embryo implantation GO:0007566 9.71 PTGS2 MMP9 MMP2
19 response to steroid hormone GO:0048545 9.69 OXTR OXT GNRH1
20 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.68 TP53 ESR1
21 regulation of neuroinflammatory response GO:0150077 9.68 PTGS2 MMP9
22 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.67 TP53 ESR1
23 maternal behavior GO:0042711 9.67 OXTR OXT
24 sleep GO:0030431 9.67 OXTR OXT
25 entry of bacterium into host cell GO:0035635 9.65 CTNNB1 CDH1
26 response to prostaglandin E GO:0034695 9.64 OXT GNRH1
27 positive regulation of uterine smooth muscle contraction GO:0070474 9.63 OXTR OXT
28 cytokine-mediated signaling pathway GO:0019221 9.63 VEGFA TP53 PTGS2 MMP9 MMP2 CXCL8
29 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.61 VEGFA TP53
30 negative regulation of gastric acid secretion GO:0060455 9.61 OXTR OXT
31 cellular response to indole-3-methanol GO:0071681 9.58 CTNNB1 CDH1
32 positive regulation of penile erection GO:0060406 9.58 OXTR OXT
33 sperm ejaculation GO:0042713 9.57 OXTR OXT
34 positive regulation of norepinephrine secretion GO:0010701 9.55 OXTR OXT
35 cellular response to UV-A GO:0071492 9.54 MMP9 MMP2 MME
36 intracellular steroid hormone receptor signaling pathway GO:0030518 9.5 PGR ESR2 ESR1
37 negative regulation of cell proliferation GO:0008285 9.5 TP53 TIMP2 PTGS2 NGF GNRH1 CXCL8
38 regulation of digestive system process GO:0044058 9.49 OXTR OXT
39 response to estradiol GO:0032355 9.1 PTGS2 OXTR OXT ESR1 CYP19A1 CTNNB1

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.17 TP53 TIMP2 PTGS2 PGR MMP9 MMP2
2 nuclear receptor activity GO:0004879 9.58 PGR ESR2 ESR1
3 steroid binding GO:0005496 9.43 PGR ESR2 ESR1
4 enzyme binding GO:0019899 9.43 TP53 PTGS2 PGR ESR2 ESR1 CTNNB1
5 estrogen receptor activity GO:0030284 9.37 ESR2 ESR1
6 steroid hormone receptor activity GO:0003707 9.33 PGR ESR2 ESR1
7 estrogen response element binding GO:0034056 9.32 ESR2 ESR1
8 zinc ion binding GO:0008270 9.23 TP53 TIMP2 PGR MMP9 MMP2 MME
Sources

Sources for Adenomyosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....